masoomeh baderi
-
Introduction
Breast cancer is among the leading causes of cancer death in women. Despite extensive efforts to identify novel prognostic and predictive clinical biomarkers, a very small number of markers have been reported as risk stratification biomarkers (e.g., BRCA1/2 and HER2). The substitution of arginine with lysine in codon 497 of HER1 497 has been suggested as a potential marker in breast cancer. This study attempted to explore the association between HER1 497 gene polymorphisms with pathological and clinical information of breast cancer patients.
Methods110 breast cancer patients were recruited followed by genomic DNA extraction and genotyping using Taqman-PCR and sequencing. The associations of this genetic variant were evaluated with breast cancer risk and pathological information of patients.
ResultsOur data showed that 9.43% of cases had AA genotype, while these frequencies in AC and CC genotypes were 77.35% and 13.20%, respectively. Moreover, we found that 78.4% of breast cancer patients with M0 had AA+AC genotypes, while 21.6% of CC cases had M0 status. Furthermore, 22.7% of these cases with CC genotype had N0/1. Interestingly, we observed that most of the patients with CC genotype had lower HER2 expression.
ConclusionsOur finding showed the potential association of CC genotype of HER1 497 with the prognosis of patients with breast cancer. Further studies are warranted to explore the prognostic value of this marker in a larger and multi-center setting in breast cancer.
Keywords: Breast Neoplasms, Genotype, Biomarkers
- در این صفحه نام مورد نظر در اسامی نویسندگان مقالات جستجو میشود. ممکن است نتایج شامل مطالب نویسندگان هم نام و حتی در رشتههای مختلف باشد.
- همه مقالات ترجمه فارسی یا انگلیسی ندارند پس ممکن است مقالاتی باشند که نام نویسنده مورد نظر شما به صورت معادل فارسی یا انگلیسی آن درج شده باشد. در صفحه جستجوی پیشرفته میتوانید همزمان نام فارسی و انگلیسی نویسنده را درج نمایید.
- در صورتی که میخواهید جستجو را با شرایط متفاوت تکرار کنید به صفحه جستجوی پیشرفته مطالب نشریات مراجعه کنید.